| Autor: |
Spratt AN; Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA., Kannan SR; Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA., Sharma K; Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India., Sachdev S; Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA., Kandasamy SL; Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA., Sönnerborg A; Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA.; Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute, 17177 Stockholm, Sweden., Lorson CL; Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA., Singh K; Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA.; Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India.; Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute, 17177 Stockholm, Sweden. |
| Abstrakt: |
The latest SARS-CoV-2 variant of concern (VOC), Omicron (B.1.1.529), has diversified into more than 300 sublineages. With an expanding number of newly emerging sublineages, the mutation profile is also becoming complicated. There exist mutually exclusive and revertant mutations in different sublineages. Omicron sublineages share some common mutations with previous VOCs (Alpha, Beta, Gamma, and Delta), indicating an evolutionary relationship between these VOCs. A diverse mutation profile at the spike-antibody interface, flexibility of the regions harboring mutations, mutation types, and coexisting mutations suggest that SARS-CoV-2's evolution is far from over. |
